Gilead: HIV Franchise Woes Highlight Cancer Follies
Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...
Zacks Investment Research on MSN17h
Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note
Gilead Sciences (GILD) ended the recent trading session at $111.88, demonstrating a +0.54% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of ...